Tibet Rhodiola Pharmaceutical Holding

Tibet Rhodiola Pharmaceutical Holding R&D per Employee

The R&D Spending per Employee of Tibet Rhodiola Pharmaceutical Holding (600211.SS) as of Oct 23, 2026 is 101,095.51 CNY. In the previous year, R&D Spending per Employee was 47,053.15 CNY — a change of 114.85% (higher).

R&D per Employee

101,095.51CNY

YoY

114.85%

Last updated:

R&D Spending per Employee of Tibet Rhodiola Pharmaceutical Holding is 2025 101,095.51 CNY. R&D Spending per Employee of Tibet Rhodiola Pharmaceutical Holding was 2024 47,053.15 CNY. It decreases by 114.85% higher compared to the previous year.

The Tibet Rhodiola Pharmaceutical Holding R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
13,345.84 CNY
Jan 1, 2019
18,007.11 CNY
Jan 1, 2020
12,128.93 CNY
Jan 1, 2021
98,955.26 CNY
Jan 1, 2022
143,301.56 CNY
Jan 1, 2023
28,211.94 CNY
Jan 1, 2024
47,053.15 CNY
Jan 1, 2025
101,095.51 CNY
The Tibet Rhodiola Pharmaceutical Holding R&D per Employee history
YEARR&D per EmployeeYoY
101,095.51CNY+114.85%
47,053.15CNY+66.78%
28,211.94CNY-80.31%
143,301.56CNY+44.81%
98,955.26CNY+715.86%
12,128.93CNY-32.64%
18,007.11CNY+34.93%
13,345.84CNY+97.38%
6,761.60CNY-44.43%
12,168.34CNY+79.83%
6,766.73CNY+47.44%
4,589.63CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Rhodiola Pharmaceutical Holding Stock analysis

What does Tibet Rhodiola Pharmaceutical Holding do? Tibet Rhodiola Pharmaceutical Holding Co. generates revenue through the manufacture and wholesale of pharmaceutical products. The company distributes proprietary drug products and processes pharmaceuticals, serving markets across South China, North China, East China, Central China, and overseas regions. Its primary customers are pharmaceutical distributors and healthcare providers within these regions, focusing on the distribution of its proprietary drug portfolio. The firm's revenue streams are derived from the wholesale of manufactured pharmaceuticals and the processing of pharmaceutical products. It operates through a network of distributors in key Chinese regions and overseas markets, targeting healthcare institutions and pharmacies that require its proprietary drug solutions. The company's business model emphasizes regional distribution networks to reach its target segments efficiently. Tibet Rhodiola Pharmaceutical Holding Co. relies on its proprietary drug products for sales, with a strong presence in multiple Chinese regions and overseas markets. The company's revenue is driven by the distribution of these products through its established wholesale channels, catering to the healthcare sector's demand for pharmaceutical solutions in its operational areas. Tibet Rhodiola Pharmaceutical Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Rhodiola Pharmaceutical Holding stock

R&D Spending per Employee of Tibet Rhodiola Pharmaceutical Holding is 101,095.51 CNY in 2025.

R&D Spending per Employee of Tibet Rhodiola Pharmaceutical Holding changed from 47,053.15 CNY to 101,095.51 CNY, representing a 114.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Tibet Rhodiola Pharmaceutical Holding since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Tibet Rhodiola Pharmaceutical Holding historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Tibet Rhodiola Pharmaceutical Holding

All Key Metrics — Tibet Rhodiola Pharmaceutical Holding